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Primary glomerulonephritis stands as the third most important cause of end-stage renal disease, suggesting that appropriate
treatment may not be as eﬀective as intended to be. Moreover, proteinuria, the hallmark of glomerular damage and a
prognostic marker of renal damage progression, is frequently resistant to thorough control. In addition, proteinuria may be
the common end pathway in which diﬀerent pathogenetic mechanisms may converge. This explains why immunosuppressive
and nonimmunosuppressive approaches are partly not suﬃcient to halt disease progression. One of the commonest causes of
primary glomerulonephritis is mesangioproliferative glomerulonephritis. Among the triggered intracellular pathways involved in
mesangial cell proliferation, the mammalian target of rapamycin (mTOR) plays a critical role in cell growth, in turn regulated
by many cytokines, disbalanced by the altered glomerulopathy itself. However, when inhibition of mTOR was studied in rodents
and in humans with primary glomerulonephritis the results were contradictory. In light of these controversial data, we propose an
explanation for these results, to dilucidate under which circumstances mTOR inhibition should be considered to treat glomerular
proteinuria and ﬁnally to propose mTOR inhibitors to be prospectively assessed in clinical trials in patients with primary
mesangioproliferative glomerulonephritis, for which a satisfactory standard immunosuppressive regimen is still pending.
1.Introduction
The universal and growing impact of chronic diseases is
undoubtedly high. While there has been little attention paid
to kidney disease on a public health level, the reality is
that many countries hardly bear the costs of providing end-
stage renal disease care through renal replacement therapy.
According to the latest USRDS report, while the prevalence
of diabetes has clearly increased and the prevalence of
congestive heart failure has remained stable, the prevalence
of chronic kidney disease appears to have declined slightly in
2009, from 15.8 percent to 15.1 percent when calculated with
the MDRD-4 formula and from 14.7 percent to 14.5 percent
when calculated with the CKD-EPI formula; prevalence
estimates of chronic kidney disease in USA in 1988–1994
had been 12.8 and 12 percent, respectively [1]. Obviously,
diﬀerences in the prevalence estimates may in part diﬀer
depending on the criteria and equations employed. Among
themostfrequentcausesofend-stagerenaldisease,glomeru-
lonephritis ranks third worldwide.
Mesangioproliferative glomerulonephritis, mostly IgA
nephropathy, is the most frequent primary glomerular
disorder worldwide, and progressive mesangioproliferative
nephropathy constitutes a major cause of end-stage renal
disease [2, 3]. Recent long-term controlled studies assessing
the prognosis have shown that the condition does not
represent a benign disorder as previously mentioned [4–7].
Once renal function impairment develops, end-stage renal
disease appears inevitable, often in the long term. Over 25
years of followup, about 30–50% of patients with IgAN
will enter renal replacement therapy [8, 9]. Other causes
of mesangial glomerulonephritis consist of pure mesangial2 International Journal of Nephrology
proliferative glomerulonephritis, IgM glomerulonephritis,
and C1q glomerulonephritis [10].
Progression in mesangioproliferative glomerulonephritis
generally involves increasing proteinuria, pathological renal
extracellular matrix protein accumulation, cell proliferation,
and inﬂammatory cell inﬁltration [11–15]. Pharmacological
treatment of progressive mesangioproliferative disease is
practically limited to renin-angiotensin system inhibition
using angiotensin-converting enzyme inhibitors or type 1
angiotensin receptor antagonists, which serves to decelerate
but is generally not capable of halting the advance of the
disease [2, 13, 15]. As recently remarked by Floege and
Eitner, there are few randomized controlled trials for IgA
nephropathy and very rarely do patient numbers exceed 200.
Consequently, most guidelines relating to IgAN are based
on a low-to-very-low level of evidence and, in many cases,
suggestions cannot even be oﬀered. Thus, the majority of
patients will continue to be treated based largely on opinion
[16]. With respect to the other causes of mesangioprolifera-
tive glomerulonephritis, in the absence of controlled trials, it
is diﬃcult to determine the eﬃcacy of therapy [10].
Administration of various immunosuppressive regimes,
containingsteroidsandcytotoxic/cytostaticdrugs,isincreas-
inglyadopted.Sincethereisnoﬁnalagreementregardingthe
antiproteinuric eﬃcacy of these protocols, which also vary
in diﬀerent disease states, and side eﬀects are important, the
clinical eﬃcacy of new immunosuppressors is increasingly
assessed [17–19]. Among these, the mammalian target of
the rapamycin (mTOR) inhibitor family, which includes
sirolimus and everolimus, is frequently used immuno-
suppressant with proliferation signal inhibitors properties
employed in nephrology [17–20]. However, serious side
eﬀects including renal injury and proteinuria have been
described during treatment with these drugs, in the setting
of renal allograft nephropathy, human glomerulonephritis
as well as in experimental kidney disease [19, 21–23].
Despite this, mTOR inhibition has been shown to be
beneﬁcial in chronic mesangioproliferative nephropathy and
to reduce proteinuria in an experimental anti-Thy1 nephri-
tis (a chronic model of progressive mesangioproliferative
nephropathy) and in focal segmental glomerulosclerosis
[24].
Aberrant proliferation of mesangial cells is a common
ﬁnding in a number of diseases that can lead to end-stage
renal failure. A variety of initial insults, which may be
metabolic(asindiabeticnephropathy)orimmunological(as
in IgA disease and lupus nephritis), can cause uncontrolled
mesangial cell proliferation. This in turn causes an increase
in extracellular matrix deposition, ultimately leading to
glomerulosclerosis, with subsequent activation of common
intermediate pathways, associated with increased synthesis
and a release of growth factors, cytokines, chemokines, and
oxidant species, which stimulate the further proliferation
of mesangial cells and ﬁnally mediating the damage of
the kidney parenchyma. It is important to understand
the proliferation mechanism of mesangial cell in order to
determine thekeyregulatorymolecularpathwaysinvolved in
the pathological response to injury and ultimately to identify




Platelet-derived growth factor (PDGF) has been recognized
as a major mitogen and one of the most important
growth factors, which mediates multiple cellular activities
such as cell proliferation, hypertrophy, and extracellular
matrix protein synthesis in various types of cells including
mesangial cells, and plays an important role in the changes
in glomerular morphology in diabetic nephropathy [25,
26] and mesangioproliferative glomerulonephritis, mainly
IgAN [27]( Figure 1). In recent years, growing evidence
suggests that adiponectin is also an important regulator
of cell proliferation. The data about its inﬂuence on cell
proliferation are conﬂicting. Some authors suggest that
adiponectin stimulates endothelial cell growth and angio-
genesis [28, 29], whereas others perceive it as a negative
regulator of cell proliferation [30, 31]. Su et al. found that
adiponectininhibitedPDGF-inducedmesangialcellprolifer-
ation. Mechanistic insights into this phenotype suggest that
adiponectin attenuates PDGF-induced phosphorylation of
mTOR via AMPK activation [25]. Interestingly, in a recent
studyithasbeenreportedthatinsubjectswithmesangialcell
proliferation, as IgAN and diabetic nephropathy, there exists
an increase of urinary adiponectin levels, which may partly
result from enhanced ﬁltration of circulating adiponectin
through the changes of glomerular permselectivity and
intraglomerular hydraulic pressure [32].
3. Regulation of mTOR
The mammalian target of rapamycin plays a critical role in
cell diﬀerentiation, migration, and survival [33–35]. mTOR
is an intracellular serine/threonine kinase and a central
component of a complex signaling network that is highly
conserved in evolutionary terms and expressed ubiquitously
throughout the cells of the body. mTOR is a component of
two major intracellular signaling complexes (mTORC1 and
mTORC2), that play diﬀerent roles downstream. mTORC1
is activated by growth factors and amino acids and controls
cellular proliferation, promoting processes such as DNA
translation, RNA transcription, ribosomal biogenesis, and
cell cycle progression [35]. Inhibitors of mTOR, such as
rapamycin or everolimus, bind to an intracellular cytoplas-
matic receptor, the FK506-binding protein-12. The complex
formedtheninteractsanddisruptsmTORfunctionandleads
to cell cycle arrest in the G1 phase. In addition to blocking
cell proliferation, mTOR inhibitors have been found to be
anti-inﬂammatory, antiﬁbrotic, antitumoral, and antifungal,
which underscores the involvement of mTOR signaling in a
wide range of cellular functions [33, 34, 36]( Figure 1). Thus,
mTOR is essential for the proliferation of mesangial cells, as
is the case of mesangioproliferative glomerulonephritis. In
this regard, in vitro studies with mice mesangial cells under
the eﬀect of diﬀerent concentrations of rapamycin showed
that a remarkably low dose (0.01ng/mL) inhibited both
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Figure 1: Hyperglycemia and PDGF stimulate mTOR, which in turn contribute to the nuclear translation of mRNAs necessary for cell
growth and proliferation, clinically evident as hematuria, proteinuria, and glomerular ﬁltration rate alterations.
this dose is below that used to produce clinically immuno-
suppressive eﬀects (4.5–14ng/mL), but could also minimize
other potential adverse drug eﬀects [37].
4. mTOR Inhibition:Low versusHigh Dose
In experimental studies, diﬀerent doses of mTORi may play
opposite eﬀects on mesangial expansion. This may appear
to be particularly true with respect to mesangioproliferative
glomerulonephritis. In this respect, low-dose rapamycin
(2.5mg/kg−1/body weight−1 in rats) confers antiproteinuric
eﬀects in a chronic model of progressive mesangioprolifera-
tive nephropathy, that is, anti-thy1-induced glomeruloscle-
rosis in the rat [36]. Brieﬂy, rapamycin remarkably limits
theprogressivecourseofchronicanti-thy1antibody-induced
renal disease towards glomerulosclerosis, tubulointerstitial
ﬁbrosis, and renal insuﬃciency. Renoprotection by low-dose
rapamycin presents beneﬁcial eﬀects on a number of key
pathways of renal disease progression, that is, proteinuria,
renal matrix protein accumulation, cell proliferation, and
leukocyte inﬁltration [12–15, 36]. Moreover, the beneﬁcial
eﬀects of mTOR inhibition have recently been reported
in several rat models of chronic kidney disease, that is,
hypertensive 5/6 nephrectomy, diabetic nephropathy, hyper-
trophy following unilateral nephrectomy, tubulointerstitial
ﬁbrosis due to uretheral obstruction or nephrotic syndrome,
and polycystic kidney disease, but not chronic transplant
glomerulopathy [38–43]. Since these experimental studies
represent the vast majority of human chronic kidney disease,
their ﬁndings together imply that mTOR signaling acts as
a rather common key pathway in the progression of renal
disease. Furthermore, these studies suggest that inhibition
of mTOR might be a novel, generally eﬀective therapeutic
approach to chronic kidney disease. However, the latter
option may also apply to early preventive treatment, since
this represents generally the timing of mTOR inhibition in
experimental rat studies. However, the outcome of mTOR
inhibition in anti-thy1-induced glomerulosclerosis contrasts
with the one previously reported in anti-thy1-induced
acute glomerulonephritis [44, 45]. In the latter, the mTOR
inhibitor everolimus before or during the early marked
mesangial cell proliferation turned out to be detrimen-
tal, manifesting aggravation of proteinuria, impaired self-
healing, increased uremic mortality, and persistent glomeru-
lar ﬁbrotic changes. These eﬀects were observed both with
high- and low-dose everolimus [44]. The studies in anti-thy1
acute and chronic renal disease unanimously indicate that
unaﬀected mTOR signaling is critical for the very early and
marked mesangial cell proliferation and subsequent normal
glomerular repair of acute anti-thy1 glomerulonephritis [36,
44, 45]. In the further course of the disease, inhibition of
mTOR even acts beneﬁcially and prevents chronic disease
progression [36]. Daniel et al. [45] reported renoprotective
eﬀect of sirolimus in experimental mesangioproliferative
glomerulonephritis. Application of everolimus as late treat-
ment for 14 weeks attenuated proteinuria and the time
course of chronic anti-Thy1 nephritis in the rat, through
reduction in vascular endothelial growth factor VEGF and
TGF-β1expression [38].
VEGF is a potent mitogen expressed in podocytes
and tubular cells that normally facilitates both glomerular
and interstitial endothelial proliferation and angiogenesis
[38, 46, 47]. Outlined by Schrijvers et al., the role of
VEGF in normal renal physiology is essentially unknown
[48]. However, VEGF and its receptors are upregulated in
experimentalanimalsandhumanswithtype1and2diabetes
and mesangioproliferative glomerulonephritis as IgAN [48–
50]. Overexpression of VEGF-A leads to glomerular collapse,
proteinuria, and end-stage renal disease in mice [50, 51]. In
subjects with early IgAN, expression of VEGF is upregulated
[52]. Some VEGF polymorphisms may be associated with
the increased risk of renal progression in patients with IgA
nephropathy [50]. Finally, VEGF expression is genetically
regulated via the mTOR pathway [53, 54] ,w h i c hi si nt u r n
wellknowntobeinhibitedbybothsirolimusandeverolimus.
In contrast to Daniel et al. [44], Ramadan et al. have
shown that either early or late low (20mg/L) but not high
doses (100mg/L) of everolimus attenuated the loss of the
slit diaphragm proteins nephrin and podocin in adriamycin-
induced nephrotic syndrome (an experimental nephropathy
that mimics minimal change disease), suggesting that the
antiproteinuric eﬀect of this agent at the therapeutic dose
is due to preservation of nephrin and podocin. Speciﬁcally,
chronic administration of everolimus at high therapeutic
doses to normal rats did not induce renal injury as expressed
by the lack of adverse eﬀects on glomerular nephrin/podocin
abundance. However, the authors speculate that this high-
dose eﬀect may be due to a decline of glomerular ﬁltration
rate and to the hypoalbuminemia seen in these rats [24].
The eﬃcacy of mTORi in mesangioproliferative glomer-
ulonephritis is limited. These potential beneﬁcial results
achieved in experimental studies are now expanding to-
wards a progressive model of human mesangioproliferative
nephropathy, an important cause of end-stage kidney disease4 International Journal of Nephrology
worldwide [2, 3]. However, clinical studies with sirolimus
are scant and showed controversial results with other causes
of glomerulonephritis. For example, while some studies
reported a rapid decline in renal function with worsening
proteinuria in patients with primary focal and segmen-
tal glomerulosclerosis [55, 56], others showed beneﬁcial
anti-proteinuric eﬀects in this disease [39, 40]. However,
with respect to mesangioproliferative glomerulonephritis
and low-dose rapamycin, an interesting and provocative
manuscript has recently been published. In this clinical
study which included 25 subjects (15 on rapamycin), it
has been shown that low-dose rapamycin plus angiotensin-
converting enzyme inhibition (enalapril 5mg/day) and sta-
tins (atorvastatin 10mg/day) stabilized renal function and
reduced glomerular proliferation in subjects with stage 3
chronic kidney disease measured with 51Cr-EDTA technique
due to IgA nephropathy with proteinuria >1g/day . At 1
year, according to Oxford classiﬁcation rapamycin treatment
was associated with a signiﬁcant reduction of mesangial
and endocapillary proliferation. Moreover, patients receiving
only angiotensin-converting enzyme inhibition and statins
lost 8mL/min/1.73m2, whereas those under rapamycin
improved by 5mL/min/1.73m2 (P = 0.03). However, scle-
rosis, chronic biopsy lesions, and proteinuria decreased
similarly in both study groups [57]. With respect to pro-
teinuria, baseline values dropped from 2.9 ± 1.8t o2 .0 ±
0.9g/day at one year, compared with the respective decrease
in the control group from 3.7 ± 1.6t o2 .8 ± 1.4g/day .The
dose of rapamycin employed was 1mg/day with through
levels between 4 and 8ng/mL, as it is usually used in
renal transplantation. Nevertheless, authors consider this
rapamycin approach as a low-dose regime, as they compare
it with a previous work by Fervenza et al. in which diﬀerent
classes of glomerulonephritis with proteinuria >1g/day
and creatinine clearance >20mL/min were treated with
rapamycin 5mg/day to seek through levels between 7 and
10ng/mL [23]. However, in this work renal function was
measured with Cockcroft-Gault equation, only 5 of the 11
subjects included had IgA nephropathy, 6 developed acute
renal failure presumably due to not-adjusted rapamycin
levels according to renal function, and no data regarding
initial or ﬁnal proteinuria are oﬀered [23]. Therefore, we
believe both studies are not comparable, and the human
“low-dose” mTORi for mesangioproliferative is still to be
determined.
Finally, mTORi are not recommended in the trans-
planted patient when proteinuria exceeds approximately
800mg/day.However,proteinuricmechanismsinthissetting
are not related to mesangial proliferation, which is the
mainculpritinmesangioproliferativeglomerulonephritis.In
addition, low dose of everolimus or rapamycin in human is
to be determined.
We believe that rapamycin and everolimus must not
be considered indistinctly as therapeutic alternatives in
glomerulardiseases.Humandoseshavenotbeenestablished,
and randomized trials in humans are required before rec-
ommendationsaremade.Whetherpreferentiallyearlyversus
late, low-versus-high doses of mTORi eﬀects on proteinuria
in mesangioproliferative GNs are due to VEGF reduced
expression, to podocin-nephrin protection, and/or to inter-
ventions in the adiponectin-PDGF binomium, among many
other possibilities, is a novel, interesting, and a promising
ﬁeld of research to assess treatment of acute mesangioprolif-
erative glomerulonephritis, for which no speciﬁc immuno-
suppressive standardized therapy exists.
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